Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

UK’s genomics leadership attracts IQVIA investment, regardless of Brexit

Invests in Genomics England alliance, plus clinical trials expansion

Lucid Group celebrate another magical year at their Winter Meeting

2018 has without doubt been a stellar year for Lucid Group, scooping a double win at Communiqué - winning both Communiqué Medical Education Consultancy of the Year and Communiqué Communications...

Lucid Group Communications Limited

Leicester NHS Trust’s staff intranet is integral to HCPs’ working day

Caroline Hastie, Operations Director of Fendix, takes a look at a typical NHS staff intranet and why it offers valuable engagement opportunities for pharma

- PMLiVE

Biogen picks up another drug from wide-ranging Ionis alliance

Aims to follow success of Spinraza

- PMLiVE

As France protests, Sanofi takes axe to 670 jobs

Layoffs latest in restructuring programme

Someone like you

Patient Influencers are becoming ubiquitous. Should we care?

- PMLiVE

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?

What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?

Page & Page Health

Personas: a top tool for personalising pharma marketing campaigns

Blue Latitude Health

What everyone forgets about good organisational change in pharma

Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account.

Blue Latitude Health

- PMLiVE

UK life sciences gets some Brexit relief with £1.3bn sector deal

Highlights commitments from Roche, IQVIA, Celgene and Autolus

- PMLiVE

Genomics England reaches 100,000th genome sequencing milestone

UK becomes world first to introduce whole genomic sequencing in clinics

- PMLiVE

Analysts lukewarm on GSK’s new cancer acquisition

Tesaro buy will leave GSK with weaker credit, says Moody’s analysts

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links